Fate Therapeutics (FATE) Tops Q3 EPS by 10c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.46), $0.10 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $1.94 million versus the consensus estimate of $1.59 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Can global equities keep rising? UBS sees these factors driving upside